Physician profile
Mohammad Farooque
NPI 1730100587
$4,244.87
in general payments reported to CMS, 2019-2025
34 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $499 · 2021: $730 · 2022: $771 · 2023: $685 · 2024: $278 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $770.58 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $435.24 | 2019-2024 | Austedo Xr, Uzedy, Austedo |
| Abbvie INC. | $339.51 | 2021-2025 | |
| Allergan, INC. | $316.41 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $293.38 | 2019-2022 | |
| Neos Therapeutics, Lp | $286.45 | 2020-2024 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $234.75 | 2019-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $181.89 | 2019-2024 | Spravato |
| Supernus Pharmaceuticals, INC. | $172.74 | 2022-2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $137.41 | 2023-2025 | Quviviq, Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.27 | 2020-2025 | Caplyta |
| Boston Scientific Corporation | $84.34 | 2019 | |
| Lundbeck LLC | $79.85 | 2020-2023 | Rexulti |
| Indivior INC. | $77.86 | 2019-2025 | Sublocade |
| Corium, LLC | $77.62 | 2022-2023 | Azstarys |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $71.01 | 2019-2022 | |
| Eisai INC. | $65.39 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $55.38 | 2021-2022 | |
| Almatica Pharma LLC | $55.20 | 2021-2022 | |
| Noven Therapeutics, LLC | $52.19 | 2020-2024 | Xelstrym |
| Adlon Therapeutics L.P. | $40.29 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $38.75 | 2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $35.24 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $32.21 | 2025 | |
| Avanir Pharmaceuticals, INC. | $30.25 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $29.60 | 2025 | Cobenfy |
| Kaleo, INC. | $28.29 | 2019 | |
| Alkermes, INC. | $25.97 | 2023 | Aristada, Lybalvi |
| Jazz Pharmaceuticals INC. | $22.58 | 2022 | |
| Tris Pharma INC | $21.46 | 2023 | Dyanavel Xr |
| Pear Therapeutics (US), INC. | $20.19 | 2021 | |
| Axsome Therapeutics, INC. | $15.33 | 2023 | Auvelity |
| Aytu Biopharma, INC. | $13.80 | 2019 | |
| Neuronetics, INC. | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Farooque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.